biotech
biotech Articles
The three biotech stocks featured here are rated Outperform at Wedbush and have at least 100% potential upside to the posted price targets.
Published:
Last Updated:
Making the move for a secondary offering after a stock has jumped massively is one way for companies to literally cash in on their recent success.
Published:
Last Updated:
Eleven Biotherapeutics announced that it has entered into a definitive agreement to acquire Viventia and its lead product candidates Vicinium and Proxinium.
Published:
Last Updated:
Shares of Puma Biotechnology had a strong gain in Tuesday’s session following some positive news from the FDA on the company's breast cancer treatment.
Published:
Last Updated:
Sarepta Therapeutics cleared another hurdle related to its Duchenne muscular dystrophy treatment, and the stock practically doubled on Monday.
Published:
Last Updated:
An RBC report noted that although headline issues such as the Federal Reserve and the election are increasing volatility, four top biotech companies may be a solid play now.
Published:
Last Updated:
Novavax was pummeled by shareholders on Friday after the company reported top-line results from its RSV F Vaccine trials.
Published:
Last Updated:
Caladrius Biosciences watched its shares soar on Thursday after the company announced a private placement offering.
Published:
Last Updated:
Sarepta Therapeutics closed out Wednesday with its shares up over 25% following positive developments surrounding eteplirsen, its treatment of Duchenne muscular dystrophy.
Published:
Last Updated:
It is not that often that you see biotech or biohealth stocks moving north of 50% in one trading session. If you do it is usually due to merger news or a rumor about a merger. In the case of Acasti...
Published:
Last Updated:
24/7 Wall St. has collected several big FDA decisions and mid- to late-stage trials that should be coming up in late-September and October.
Published:
Last Updated:
Despite recent market headwinds and volatility, there are strong underlying fundamentals among the large cap pharmaceuticals that are continuing to drive them forward.
Published:
Last Updated:
The August 31 short interest data have been compared with the previous report, and short interest decreased for most of these selected biotech stocks.
Published:
Last Updated:
Investors never like to see a stock they own drop 17%, but there is at least one view that maybe the drop is an opportunity for those with longer-term views who remain bullish.
Published:
Last Updated:
Some biotech companies made impressive runs over the course of this past week. These select few stood out from the rest.
Published:
Last Updated: